New First-Line Systemic Treatment Options for Metastatic Esophageal Squamous Cell Carcinoma
Clinicians should be aware of the data supporting the use of immune checkpoint inhibitors, including nivolumab, in patients with various presentations of esophageal or esophagogastric junction cancers to identify the patients most likely to benefit from this treatment strategy.
Category
  • Gastric/Esophageal Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Radiation Therapy for Metastatic Brain Tumors
Whole-brain radiation therapy was historically the mainstay of treatment for brain metastases but has fallen out of favor in clinical practice over the last several decades. Strategies to promote cognitive preservation in patients with brain metastases is an area of active investigation. Clinicians need to remain up to date on these strategies.
Category
  • Central Nervous System Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Hereditary/Familial Ovarian Cancer: Testing Principles and Risk Management
Studies suggest a benefit of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk in carriers of a BRCA1/2 pathogenic/likely pathogenic (P/LP) variant, but the magnitude of the effect is not well-understood, and evidence is mixed regarding age at which RRSO should be undertaken and the specific P/LP variant (BRCA1 vs. BRCA2) carried. More data are needed regarding the efficacy of salpingectomy without oophorectomy in reducing the risk for ovarian cancer in carriers of a BRCA1/2 P/LP variant.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Management of Relapsed/Refractory Multiple Myeloma
Understanding optimal sequencing for patients with relapsed/refractory multiple myeloma can be a challenge in clinical practice. A uniform treatment approach cannot be applied to all patients. Physicians and other care providers must understand the evolving therapeutic options in the context of the patient's therapeutic and disease history to navigate through the complex treatment landscape.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Management of Metastatic Prostate Cancer
Clinicians need to be educated on results of recent trials and on updates to the NCCN Guidelines for Prostate Cancer recommendations so that they can provide optimal disease management for patients with metastatic prostate cancer.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Updates on the Management of Immunotherapy-Related Toxicities
As the field of cancer immunotherapy continues to evolve, clinicians need to be informed about the most up-to-date strategies for managing immunotherapy-related toxicities. Providing continuing education on early recognition and effective management of immunotherapy-related toxicities is crucial to ensure optimal outcomes for an increasing number of patients treated with immunotherapy.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Plenary Session: Health System Recruitment and Retention Strategies
The staffing challenges cancer centers are experiencing as a result of the pandemic are unprecedented. Cancer centers may need to develop new strategies to improve staff recruitment and retention in today’s environment.
Category
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
The treatment landscape for ovarian, fallopian tube, and primary peritoneal cancers has significantly evolved in recent years due to new FDA approvals and emerging clinical data on available targeted therapies. Continuing education is, therefore, essential for clinicians to stay informed about the efficacy and safety data for these systemic therapy options.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Advances in the Management of Metastatic Breast Cancer
With expanding treatment options, clinicians should understand important criteria used in selecting optimal first-and subsequent-line therapies for individuals with metastatic breast cancer. For clinicians, staying up to date with the available treatment options is important to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profiles is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Programs to Reduce Hospital Admissions and Readmissions
Education about this topic is important because reducing hospital admissions is a measure for demonstrating the quality of care cancer centers provide. Additionally, centers planning to participate in the Enhancing Oncology Model (EOM) will be required to track this measure.
Category
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation

Pages